BDBM620215 (2R,3R,4S,5R,6R)-2-((8,8-difluoro-1-oxa-2-azaspiro[4.5]dec-2-en-3- yl)methyl)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy- 6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl acetate::US20230295182, Example 1.03

SMILES CC(=O)O[C@H]1[C@@H](CC2=NOC3(C2)CCC(F)(F)CC3)O[C@H](CO)[C@H](O)[C@@H]1n1cc(nn1)-c1ccc(C)c(F)c1F

InChI Key InChIKey=NYMYHXASTIYJKQ-UHFFFAOYSA-N

Data  2 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 2 hits for monomerid = 620215   

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620215(US20230295182, Example 1.03 | (2R,3R,4S,5R,6R)-2-(...)
Affinity DataIC50: 79nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetGalectin-1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620215(US20230295182, Example 1.03 | (2R,3R,4S,5R,6R)-2-(...)
Affinity DataIC50: 1.00E+5nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent